EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients
Public ClinicalTrials.gov record NCT04998604. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Head-to-head Comparison of Dupilumab Versus Omalizumab in Severe Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) and Comorbid Asthma Patients
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Primary Objective -To evaluate the efficacy of dupilumab compared to omalizumab in reducing the polyp size and improving sense of smell Secondary Objectives * To evaluate the efficacy of dupilumab in improving chronic rhinosinusitis with nasal polyps (CRSwNP) symptoms at Week 24 compared to omalizumab * To evaluate the efficacy of dupilumab in improving CRSwNP total symptom score (TSS) at Week 24 compared to omalizumab * To evaluate the effect of dupilumab on health related quality of life (HRQoL) at week 24 compared to omalizumab * To evaluate the efficacy of dupilumab in improving nasal peak inspiratory flow at Week 24 compared to omalizumab * To evaluate the effect of dupilumab on CRSwNP overall disease severity at Week 24 compared to omalizumab * To evaluate the safety of dupilumab and omalizumab
Study identification
- NCT ID
- NCT04998604
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 360 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 27, 2021 (Actual)
- Primary completion
- Oct 16, 2024 (Actual)
- Completion
- Dec 27, 2024 (Actual)
- Last update posted
- Oct 23, 2025
2021 – 2024
United States locations
- U.S. sites
- 16
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Cedars Sinai Medical Center Site Number : 8400026 | Los Angeles | California | 90048 | — |
| Asthma Allergy & Immunology Clinical Research Unit Site Number : 8400027 | Tampa | Florida | 33613 | — |
| Northwestern University Site Number : 8400001 | Chicago | Illinois | 60611 | — |
| University of Illinois | Chicago | Illinois | 60612 | — |
| Advanced ENT and Allergy Site Number : 8400013 | Louisville | Kentucky | 40220 | — |
| University of Missouri Health Care - University Hospital Site Number : 8400016 | Columbia | Missouri | 65212 | — |
| Northwell Health Site Number : 8400044 | Great Neck | New York | 11021 | — |
| University of Rochester Site Number : 8400015 | Rochester | New York | 14642 | — |
| Cleveland Clinic Foundation Site Number : 8400029 | Cleveland | Ohio | 44195 | — |
| Optimed Research, LTD Site Number : 8400014 | Columbus | Ohio | 43235 | — |
| Allergy, Asthma and Clinical Research Center Site Number : 8400037 | Oklahoma City | Oklahoma | 73120 | — |
| Essential Medical Research, LLC Site Number : 8400024 | Tulsa | Oklahoma | 74137 | — |
| Oregon Health & Science University Site Number : 8400031 | Portland | Oregon | 97239 | — |
| University of Texas Health Science Center- Site Number : 8400019 | Houston | Texas | 77030 | — |
| Chryaslis Clinical Research Site Number : 8400017 | St. George | Utah | 84790 | — |
| Eastern Virginia Medical School Site Number : 8400010 | Norfolk | Virginia | 23507 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 71 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04998604, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 23, 2025 · Synced Oct 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04998604 live on ClinicalTrials.gov.